HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Colgate and ADA team up

This article was originally published in The Rose Sheet

Executive Summary

Colgate-Palmolive has signed on to be a national strategic partner of the American Diabetes Association, backing ADA's oral-care activities "which will seek to further the understanding of the connection between oral health and diabetes," according to April 2 release. ADA and Colgate will collaborate on educating patients, healthcare professionals and the public about the "importance of good oral care for people with diabetes" and for those at risk of developing the disease. Diabetes patients are estimated to be 2 to 5 times more likely to develop gum disease than people without diabetes, according to the association. Colgate additionally will support ADA's "Ask the Dentist" online chat series and the oral hygiene section of 1www.diabetes.org...

You may also be interested in...



Serum Institute-Novavax Seal Win-Win Deal For COVID-19 Vaccine

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in a few regions. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India till deal ends and non-exclusive rights for developing countries till pandemic lasts, with Novavax getting half of net revenue.

Infographic: Heart Failure Market Set To Reach Almost $12.5Bn In 2022

The market for heart failure diagnostics and devices is set to grow by 3.8% annually in the next three years, with emerging markets leading the growth, according to the new Meddevicetracker Dashboard.

Rosemont Deal Shows Value Is Out There For US Exit, Perrigo Says

Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel